PHIL™ Middle Meningeal Artery Embolization for First-Line Treatment of Chronic Subdural Hematoma IDE Trial

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age22+
SponsorMicrovention-Terumo, Inc.

About this trial

This is a prospective, randomized, controlled, open-label, blinded endpoint (PROBE) clinical investigation in which patients with non-emergent chronic subdural hematoma (cSDH) requiring treatment will be randomized (1:1) to either initial surgical evacuation (Control Arm) or initial MMAE with PHIL™ (investigational arm).

Eligibility criteria

Qualifiers

Age 22 years or older

Diagnosis of chronic subdural hematoma

Subject, or their legally authorized representative provides a signed and dated Informed Consent Form

Pre-morbid mRS 0-1

Disqualifiers

Prior ipsilateral craniotomy or burr hole evacuation of cSDH

Prior embolization of either MMA

Requires (in the opinion of the treating surgeon) full or mini-craniotomy at time of randomization

Emergent subdural hematoma evacuation needed

Trial design

Treatments tested in this trial

  • PHIL™ (Precipitating Hydrophobic Injectable Liquid)
  • Surgical evacuation

Treatment groups

475 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators